All Stories

  1. Platelet count threshold for lumbar puncture: Does one size really fit all?

    Article • Transfusion, September 2020, Wiley

    Dr Ahmet Emre Eskazan

  2. Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor

    Article • Cancer Reports, September 2020, Wiley

    Dr Ahmet Emre Eskazan

  3. Copy number variations in adult patients with chronic immune thrombocytopenia

    Article • Expert Review of Hematology, September 2020, Taylor & Francis

    Dr Ahmet Emre Eskazan

  4. Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes

    Article • Journal of Blood Medicine, September 2020, Taylor & Francis

    Dr Ahmet Emre Eskazan

  5. Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

    Article • Expert Review of Hematology, August 2020, Taylor & Francis

    Dr Ahmet Emre Eskazan

  6. COVID‐19 presenting with immune thrombocytopenia: a case report and review of the literature

    Article • Journal of Medical Virology, June 2020, Wiley

    Dr Ahmet Emre Eskazan

  7. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID‐19 pandemic

    Article • British Journal of Clinical Pharmacology, May 2020, Wiley

    Dr Ahmet Emre Eskazan

  8. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML

    Article • Future Oncology, May 2020, Future Medicine

    Dr Ahmet Emre Eskazan

  9. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation

    Article • Journal of Oncology Pharmacy Practice, April 2020, SAGE Publications

    Dr Ahmet Emre Eskazan

  10. Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?

    Article • Leukemia, March 2020, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  11. Novel therapeutic approaches in chronic myeloid leukemia

    Article • Leukemia Research, February 2020, Elsevier

    Dr Ahmet Emre Eskazan

  12. Bosutinib – an effective and safe treatment option in the management of chronic myeloid leukemia

    Article • Future Oncology, January 2020, Future Medicine

    Dr Ahmet Emre Eskazan

  13. Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost‐effective?

    Article • Cancer, November 2019, Wiley

    Dr Ahmet Emre Eskazan

  14. The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience

    Article • Laboratory Medicine, September 2019, Oxford University Press (OUP)

    Dr Ahmet Emre Eskazan, Dr Mustafa Sevinc

  15. New drugs approved for acute myeloid leukemia (AML) in 2018

    Article • British Journal of Clinical Pharmacology, August 2019, Wiley

    Dr Ahmet Emre Eskazan

  16. Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia

    Article • Oncology and Therapy, August 2019, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  17. Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukemia are associated with hematologic toxicities – which TKI is the safest?

    Article • British Journal of Clinical Pharmacology, August 2019, Wiley

    Dr Ahmet Emre Eskazan

  18. The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J. Klil-Drori et al., Haematologica 2019;104(7):e293)

    Article • Haematologica, June 2019, Ferrata Storti Foundation (Haematologica)

    Dr Ahmet Emre Eskazan

  19. An alternative way – tyrosine kinase inhibitor (TKI) de-escalation – to discontinue TKIs in order to achieve treatment-free remission

    Article • Expert Review of Hematology, June 2019, Taylor & Francis

    Dr Ahmet Emre Eskazan, ahmad kunbaz

  20. The outcomes of chronic myeloid leukemia patients with molecular warning responses under imatinib according to the European LeukemiaNet (ELN) 2013 recommendations

    Article • Clinical Lymphoma Myeloma & Leukemia, April 2019, Elsevier

    Dr Ahmet Emre Eskazan

  21. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura

    Article • Drug Design Development and Therapy, April 2019, Dove Medical Press

    Dr Ahmet Emre Eskazan

  22. Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?

    Article • Leukemia & Lymphoma, February 2019, Taylor & Francis

    Dr Ahmet Emre Eskazan

  23. Coexistence of Hermansky-Pudlak syndrome and JAK2V617F-positive essential thrombocythemia

    Article • Ultrastructural Pathology, January 2019, Taylor & Francis

    Dr Ahmet Emre Eskazan, Muhlis Cem Ar, BASAK ISILDAR

  24. Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?

    Article • Clinical and Applied Thrombosis/Hemostasis, January 2019, SAGE Publications

    Dr Ahmet Emre Eskazan

  25. Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?

    Article • Cancer, October 2018, Wiley

    Dr Ahmet Emre Eskazan

  26. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

    Article • Leukemia Research, September 2018, Elsevier

    Dr Ahmet Emre Eskazan

  27. Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword

    Article • Acta Oncologica, August 2018, Taylor & Francis

    Dr Ahmet Emre Eskazan

  28. Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors

    Article • Leukemia & Lymphoma, July 2018, Taylor & Francis

    Dr Ahmet Emre Eskazan, Muhlis Cem Ar

  29. Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single Institution Experience

    Article • Balkan Medical Journal, July 2018, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  30. Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?

    Article • British Journal of Clinical Pharmacology, June 2018, Wiley

    Dr Ahmet Emre Eskazan

  31. The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis

    Article • Journal of Medical Economics, May 2018, Taylor & Francis

    Dr Ahmet Emre Eskazan

  32. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia

    Article • Cancer, April 2018, Wiley

    Dr Ahmet Emre Eskazan

  33. Dasatinib-Induced Pulmonary Arterial Hypertension

    Article • British Journal of Clinical Pharmacology, January 2018, Wiley

    Dr Ahmet Emre Eskazan

  34. Cytopenia in adult brucellosis patients

    Article • The Indian Journal of Medical Research, January 2018, Medknow

    Dr Ahmet Emre Eskazan

  35. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience

    Article • Turkish Journal of Hematology, December 2017, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  36. Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib

    Article • International Journal of Clinical Oncology, November 2017, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  37. Midostaurin in FLT3-Mutated Acute Myeloid Leukemia

    Article • New England Journal of Medicine, November 2017, New England Journal of Medicine (NEJM/MMS)

    Dr Ahmet Emre Eskazan

  38. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature

    Article • Hematology, October 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  39. Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience

    Article • Turkish Journal of Hematology, September 2017, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  40. Outcome of Chronic Myeloid Leukemia Patients with Early Molecular Response at 3 and 6 months: a Comparative Analysis of Generic Imatinib and Glivec

    Article • Clinical Lymphoma Myeloma & Leukemia, August 2017, Elsevier

    Dr Ahmet Emre Eskazan

  41. Vascular adverse events under long-term nilotinib therapy in patients with chronic myeloid leukemia

    Article • Clinical Lymphoma Myeloma & Leukemia, August 2017, Elsevier

    Dr Ahmet Emre Eskazan

  42. Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update

    Article • Therapeutic Advances in Hematology, July 2017, SAGE Publications

    Dr Ahmet Emre Eskazan

  43. Comment and response to: the significance of early warning in chronic myeloid leukemia

    Article • Expert Review of Hematology, June 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  44. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events – is better always good?

    Article • Expert Review of Hematology, June 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  45. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed-Refractory to IMiDs and Proteasome Inhibitors

    Article • Turkish Journal of Hematology, March 2017, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  46. Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

    Article • Leukemia & Lymphoma, February 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  47. Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase

    Article • Expert Opinion on Pharmacotherapy, January 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  48. Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?

    Article • Leukemia & Lymphoma, January 2017, Taylor & Francis

    Dr Ahmet Emre Eskazan

  49. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

    Article • Drug Design Development and Therapy, October 2016, Dove Medical Press

    Dr Ahmet Emre Eskazan

  50. Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura

    Article • Annals of Hematology, September 2016, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  51. Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting

    Article • European Journal of Clinical Pharmacology, August 2016, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  52. Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in a Developing Country

    Article • Clinical Therapeutics, March 2016, Elsevier

    Dr Ahmet Emre Eskazan

  53. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

    Article • Journal of Clinical Pathology, January 2016, BMJ

    Dr Ahmet Emre Eskazan

  54. Pleural tuberculosis in a patient with untreated type 1 Gaucher disease

    Article • Journal of Infection and Chemotherapy, January 2016, Elsevier

    Dr Ahmet Emre Eskazan

  55. Comparison of International Prognostic Index and NCCN-IPI in 324 patients withde novodiffuse large B-cell lymphoma: a multi-center retrospective analysis

    Article • Leukemia & Lymphoma, October 2015, Taylor & Francis

    Dr Ahmet Emre Eskazan

  56. Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha

    Article • Indian Journal of Hematology and Blood Transfusion, September 2015, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  57. Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy

    Article • The Turkish Journal of Gastroenterology, April 2015, AVES Publishing Co.

    Dr Ahmet Emre Eskazan

  58. Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?

    Article • Leukemia & Lymphoma, March 2015, Taylor & Francis

    Dr Ahmet Emre Eskazan

  59. Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpaşa experience

    Article • Journal of Oncology Pharmacy Practice, February 2015, SAGE Publications

    Dr Ahmet Emre Eskazan

  60. Treatment and Outcome of Primary and Secondary Thrombotic Microangiopathies

    Article • American Journal of Nephrology, January 2015, Karger Publishers

    Dr Ahmet Emre Eskazan

  61. Second primary malignancies in chronic myeloid leukemia patients

    Article • Journal of Cancer Research and Therapeutics, January 2015, Medknow

    Dr Ahmet Emre Eskazan

  62. Radotinib in the treatment of chronic phase chronic myeloid leukemia patients

    Article • Haematologica, December 2014, Ferrata Storti Foundation (Haematologica)

    Dr Ahmet Emre Eskazan

  63. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options

    Article • Turkish Journal of Hematology, December 2014, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  64. The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment

    Article • Leukemia & Lymphoma, November 2014, Taylor & Francis

    Dr Ahmet Emre Eskazan

  65. Spondylodiscitis: evaluation of patients in a tertiary hospital

    Article • The Journal of Infection in Developing Countries, October 2014, Journal of Infection in Developing Countries

    Dr Ahmet Emre Eskazan, Serdar Ercan

  66. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence

    Article • Expert Review of Hematology, October 2014, Taylor & Francis

    Dr Ahmet Emre Eskazan

  67. The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?

    Article • Leukemia & Lymphoma, August 2014, Taylor & Francis

    Dr Ahmet Emre Eskazan

  68. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion

    Article • Leukemia Research, July 2014, Elsevier

    Dr Ahmet Emre Eskazan

  69. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

    Article • British Journal of Haematology, May 2014, Wiley

    Dr Ahmet Emre Eskazan

  70. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia

    Article • Leukemia & Lymphoma, May 2014, Taylor & Francis

    Dr Ahmet Emre Eskazan

  71. The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study

    Article • Turkish Journal of Hematology, March 2014, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  72. Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature

    Article • Rheumatology, February 2014, Oxford University Press (OUP)

    Dr Ahmet Emre Eskazan

  73. Two Cases of Autoimmune Hemolytic Anemia Secondary to Brucellosis: A Review of Hemolytic Disorders in Patients with Brucellosis

    Article • Internal Medicine, January 2014, Japanese Society of Internal Medicine

    Dr Ahmet Emre Eskazan

  74. Postoperative thrombotic thrombocytopenic purpura

    Article • Surgery Today, December 2013, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  75. Brucellar pericarditis: a report of four cases and review of the literature

    Article • International Journal of Infectious Diseases, June 2013, Elsevier

    Dr Ahmet Emre Eskazan

  76. B-Cell Chronic Lymphocytic Leukemia and Colon Adenocarcinoma in the Same Mesenteric Lymph Node

    Article • Turkish Journal of Hematology, March 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  77. Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia

    Article • Turkish Journal of Hematology, February 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  78. Diagnostic dilemma: metastatic bone malignancy or primary hyperparathyroidism with brown tumor

    Article • Open Journal of Internal Medicine, January 2013, Scientific Research Publishing, Inc,

    Dr Ahmet Emre Eskazan

  79. Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia

    Article • Turkish Journal of Hematology, January 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  80. Acute Acalculous Cholecystitis due to Viral Hepatitis A

    Article • Case Reports in Infectious Diseases, January 2013, Hindawi Publishing Corporation

    Dr Ahmet Emre Eskazan

  81. Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia

    Article • Turkish Journal of Hematology, January 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  82. Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study

    Article • ISRN Hematology, January 2013, Hindawi Publishing Corporation

    Dr Ahmet Emre Eskazan

  83. Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients

    Article • Turkish Journal of Hematology, January 2013, Journal of Clinical Research of Pediatric Endocrinology

    Dr Ahmet Emre Eskazan

  84. Breast schwannoma in a patient with diffuse large B-cell lymphoma: a case report

    Article • Journal of Medical Case Reports, December 2012, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  85. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature

    Article • Transfusion, November 2012, Wiley

    Dr Ahmet Emre Eskazan

  86. Successful Management of Chronic Refractory Immune Thrombocytopenia with Laparoscopic Splenectomy in a Patient with Acute Promyelocytic Leukemia

    Article • Indian Journal of Hematology and Blood Transfusion, July 2012, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  87. Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature

    Article • Transfusion, January 2012, Wiley

    Dr Ahmet Emre Eskazan

  88. Hypereosinophilic Syndrome Associated with Simultaneous Intracardiac Thrombi, Cerebral Thromboembolism and Pulmonary Embolism

    Article • Internal Medicine, January 2012, Japanese Society of Internal Medicine

    Dr Ahmet Emre Eskazan

  89. The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

    Article • Turkish Journal of Hematology, January 2012, LookUs Bilisim, Ltd.

    Dr Ahmet Emre Eskazan

  90. Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2011, Elsevier

    Dr Ahmet Emre Eskazan

  91. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?

    Article • Leukemia Research, September 2011, Elsevier

    Dr Ahmet Emre Eskazan

  92. Thrombotic Thrombocytopenic Purpura After Prophylactic Cefuroxime Axetil Administered in Relation to a Liposuction Procedure

    Article • Aesthetic Plastic Surgery, August 2011, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  93. Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients

    Article • Turkish Journal of Hematology, August 2011, LookUs Bilisim, Ltd.

    Dr Ahmet Emre Eskazan

  94. ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method

    Article • Turkish Journal of Hematology, June 2011, LookUs Bilisim, Ltd.

    Dr Ahmet Emre Eskazan

  95. Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm

    Article • Annals of Hematology, May 2011, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  96. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy

    Article • Haematologica, February 2011, Ferrata Storti Foundation (Haematologica)

    Dr Ahmet Emre Eskazan

  97. Primary Gastrointestinal Diffuse Large B Cell Lymphoma Presenting with Cold Agglutinin Disease

    Article • Case Reports in Gastroenterology, January 2011, Karger Publishers

    Dr Ahmet Emre Eskazan

  98. Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi’s Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence

    Article • Case Reports in Oncology, January 2011, Karger Publishers

    Dr Ahmet Emre Eskazan

  99. Intracranial mass in a patient with thalassaemia major

    Article • British Journal of Haematology, November 2010, Wiley

    Dr Ahmet Emre Eskazan

  100. Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports

    Article • Journal of Medical Case Reports, January 2009, Springer Science + Business Media

    Dr Ahmet Emre Eskazan

  101. Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia

    Article • Biotechnology & Biotechnological Equipment, January 2009, Taylor & Francis

    Dr Ahmet Emre Eskazan

  102. Primary Cutaneous Immunocytoma/Marginal Zone B-Cell Lymphoma: A Case with Unusual Course

    Article • American Journal of Dermatopathology, April 2004, Wolters Kluwer Health

    Dr Ahmet Emre Eskazan